Daratumumab for Anti‐ <scp>HLA</scp> Antibody Desensitization and Antibody Mediated Rejection in Pediatric Heart Transplant Patients
We report that daratumumab is safe and effective in a small series of pediatric heart transplant patients, including patients as young as 6 months old. Daratumumab could prove to be a valuable tool for desensitization and AMR treatment; however, additional studies are needed to corroborate these findings and determine long-term outcomes.
Authors
- Heather Bastardi (ORCID: https://orcid.org/0009-0006-6146-4230)
- Alanna Wong
- Tajinder P. Singh (ORCID: https://orcid.org/0000-0001-7310-7966)
- Paul Esteso (ORCID: https://orcid.org/0000-0003-3697-6972)
- Kevin P. Daly (ORCID: https://orcid.org/0000-0003-4327-1532)
- Caitlin Milligan (ORCID: https://orcid.org/0000-0001-5347-4400)
Institutions
- Boston Children's Hospital (US)
- Harvard University (US)
- Boston Children's Museum (US)
Publication Details
- Journal
- Pediatric Transplantation
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1111/petr.70106
- Citations
- 3
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- National Institutes of Health